Medicine for improving thyroid-associated ophthalmopathy and application thereof

The delivery of IGF1R single-chain antibody (scFv) through a recombinant adeno-associated virus vector solves the problem of frequent infusion in the treatment of thyroid-related eye diseases, achieves long-term inhibition of cell proliferation, reduces medication frequency and side effects, and improves treatment compliance.

CN120757642APending Publication Date: 2025-10-10SHENYANG KANGRUISHENG BIOTECHNOLOGY CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202510748637.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-06-07
Filing Date
2025-06-06
Publication Date
2025-10-10

AI Technical Summary

Technical Problem

Existing treatments for thyroid-related eye diseases require frequent infusions of monoclonal antibodies, which imposes a huge treatment burden on patients. Traditional monoclonal antibodies also require high dosing frequencies and have significant side effects.

Method used

A recombinant adeno-associated virus vector is used to carry a single-chain antibody (scFv fragment) of an anti-IGF1R antibody, which is expressed in the body for a long time through gene therapy, thereby inhibiting the activity of IGF1R, reducing the frequency of administration, and reducing side effects.

Benefits of technology

By delivering IGF1R single-chain antibody (scFv) through AAV vector, long-term and effective inhibition of cell proliferation can be achieved, medication frequency can be reduced, patient compliance can be improved, and treatment risks can be reduced.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to a medicine for improving thyroid-related eye diseases and application of the medicine. The single-chain antibody provided by the invention has small molecular weight and good physiological activity, and can effectively inhibit the activity and function of IGF1R mediated by IGF1, thereby inhibiting cell proliferation. According to the medicine prepared from the recombinant adeno-associated virus, the treatment cost can be remarkably reduced, side effects caused by repeated injection of antibody medicines are avoided, the safety is very high, and a new clinical treatment method and strategy are provided for inhibiting pathological phenotypes of thyroid-associated ophthalmopathy.
Need to check novelty before this filing date? Find Prior Art